🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are on the rise globally, with estimates suggesting over 82 million new cases each year. Notably increased rates are reported in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of growing infection rates, increasing antimicrobial resistance and the very limited available drugs at this time.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This milestone represents a huge turning point in the therapy of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Data and Worldwide Availability

Based on data detailed in a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which uses a dual-drug approach. The study included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians treating patients have shared positive views. Access to a single-dose, oral treatment such as this is described as a "critical tool" for gonorrhoea control. This is considered essential to alleviate the strain of the illness for people and to halt the transmission of untreatable gonorrhoea around the world.